BriefMD

Specialties / Addiction Medicine

New Addiction Medicine research.

The strongest recent Addiction Medicine papers on PubMed, ranked by study design, topic and journal, with the same summaries subscribers get.

  1. randomized trial, 31 patients

    Altered GABAB receptor sensitivity in heavy drinkers indexed using a TMS-based biomarker: a randomized controlled experimental medicine trial

    Montemitro C, Donahue D, Costumati A, et al. Transl Psychiatry. Oct 2026.

    Findings
    In light drinkers, baclofen at 30 mg potentiated LICI and a similar effect was seen at 60 mg, while in heavy drinkers the potentiation was present at 30 mg but absent at 60 mg despite similar drug levels.
    Bottom line
    Heavy drinkers show reduced LICI response at 60 mg baclofen compared with light drinkers.

    PubMed, PMID 42918748

  2. meta-analysis, 13 studies

    Oral Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack: Systematic Review and Meta-Analysis

    Arshad MA, Nadeem H, Afzal M, et al. Brain Behav. Oct 2026.

    Findings
    A meta‑analysis of three trials (16,501 participants) found that FXIa inhibition reduced recurrent ischemic stroke (413/6927 vs. 579/7312; RR 0.74, 95% CI 0.65‑0.84).
    Bottom line
    FXIa inhibitors lower recurrent stroke risk (RR 0.74) without a significant rise in major bleeding.

    PubMed, PMID 42922031

  3. phase ii trial, 59 patients

    Safety and efficacy of psilocybin-assisted therapy for alcohol use disorder: Open-label extension of a phase II randomized controlled trial

    Pagni BA, Ross S, Mennenga S, et al. Drug Alcohol Depend. Oct 2026.

    Findings
    In an open‑label extension, 59 adults with alcohol use disorder were given a single psilocybin administration of 25‑40 mg per 70 kg body weight, accompanied by four hours of manualized therapy. The treatment was well tolerated and no serious adverse events occurred.
    Bottom line
    A single 25‑40 mg/70 kg psilocybin dose plus four hours of therapy was safe for 59 participants.

    PubMed, PMID 42913354

  4. systematic review, 29 studies

    Harm reduction among refugees and displaced populations in Lebanon: a systematic review

    Abbas Z, Hajj A, Sacre H, et al. Harm Reduct J. Jul 2026.

    Findings
    The review included 29 studies, finding a lack of structured policies and that only four of twelve grey‑literature documents mentioned harm‑reduction provision.
    Bottom line
    Evidence shows major policy gaps, with few documents addressing harm reduction for refugees.

    PubMed, PMID 42894244

Summaries are written by AI from PubMed abstracts, for keeping up with the literature. Check the source before it changes care. Editorial policy · Medical disclaimer

Get Addiction Medicine research every morning.

Free. Choose your Addiction Medicine topics after you subscribe.